Page 36 of 95
Previous Page     Next Page        Smaller fonts | Larger fonts     Go back to the flash version

36

nanotimes

Companies Facts

near perfect multi-language speech recognition with a virtual 15-inch PC display, the Golden-i headset provides immediate hands-free access to nearly any digital information in the world and the ability to remotely control most wireless devices. http://www.kopin.com

L iquidmetal® Technologies Inc. (OTCBB: LQMT) and The Swatch Group Ltd. (SWX: UHR/UHR N)

have signed an exclusive licensing agreement, allow- ing the Swiss manufacturer to utilize the Liquidmetal alloy technology worldwide.

Within the Swatch Group, the Liquidmetal techno- logy has been used for the first time in 2009 for the Omega Seamaster Planet Ocean, and in 2010 for the Breguet „Reveil musical.“ The present contract will allow The Swatch Group to use the technology exclusively in their entire line of timepieces. The Company reported its financial results for the three months and year ended December 31, 2010. The Company reported revenues of $11.1 million and $33.0 million for the fourth quarter and fiscal year ending December 31, 2010, respectively. Further- more, the Company closed out the quarter and year end with operating income of $4.8 million and $15.7 million, respectively.

Mr. Tom Steipp, President and CEO, commented, “We are pleased with the results of the year and pro- gress made to date in leveraging a growing number of marquee partnerships into a sustainable business model. The most recent announcement on March 10, 2011 with Swatch is just another indicator of the significant interest that we are seeing in the market for Liquidmetal technology.” http://www.liquidmetal.com

M

agForce Nanotechnologies AG (FSE:MF6), a leader in nanomedicine-based cancer treat-

ment, announced that its sales and marketing team for Germany is in place and commercialization acti- vities are set to begin. With a Commercial Director and four key account managers in place, MagForce will now seek to make its NanoTherm®

therapy

available in clinics across Germany. The company has received EU approval for its medical devices, which use magnetic nanoparticles for the treatment of brain tumors. Through the application of an alter- nating magnetic field, the nanoparticles are activa- ted, and heat is produced from within the tumor.

Solveig Salomon joins the company as European Commercial Director and will lead the commerciali- zation team. She has over twenty years of experience in the pharmaceutical industry, including sales and marketing experience in the area of oncology. Her professional experience includes leading positions held at Sandoz International GmbH, Amgen GmbH, Janssen-Cilag GmbH, and Grünenthal GmbH. The German MagForce Nanotechnologies is a lea- der in nanomedicine-based cancer treatment and focused on the treatment of solid tumors. The company‘s proprietary procedure, NanoTherm®

the-

rapy, enables the targeted treatment of solid tumors through the intratumoral release of heat from ma- gnetic nanoparticles. NanoTherm®

, NanoPlan®

NanoActivator™ are components of the therapy. http://www.magforce.com

M

iaSolé, the leading manufacturer of copper indium gallium selenide (CIGS) thin-film

photovoltaic solar panels, announced that the U.S. Department of Energy‘s National Renewable Ener- gy Laboratory (NREL) independently confirmed the

, and

11-02/03 :: February / March 2011

Previous arrowPrevious Page     Next PageNext arrow        Smaller fonts | Larger fonts     Go back to the flash version
1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  |  15  |  16  |  17  |  18  |  19  |  20  |  21  |  22  |  23  |  24  |  25  |  26  |  27  |  28  |  29  |  30  |  31  |  32  |  33  |  34  |  35  |  36  |  37  |  38  |  39  |  40  |  41  |  42  |  43  |  44  |  45  |  46  |  47  |  48  |  49  |  50  |  51  |  52  |  53  |  54  |  55  |  56  |  57  |  58  |  59  |  60  |  61  |  62  |  63  |  64  |  65  |  66  |  67  |  68  |  69  |  70  |  71  |  72  |  73  |  74  |  75  |  76  |  77  |  78  |  79  |  80  |  81  |  82  |  83  |  84  |  85  |  86  |  87  |  88  |  89  |  90  |  91  |  92  |  93  |  94  |  95